Shamburg News · 8-K filed Nov 17, 2026, 9:01 AM EST

MetaVia Completes Last Patient Visit in Phase 1 Part 3A Study of DA-1726

MTVA · MetaVia Inc.

  • Other event
  • Reg FD disclosure
  • Materiality: medium

MetaVia Inc. announced on November 17, 2026 that the last patient has completed the final study visit in its Phase 1 clinical trial of DA-1726, a GLP-1/glucagon dual-receptor agonist. The company extended the treatment period from 16 to 24 weeks, with patients receiving 48 mg weekly for an additional eight weeks. Full data from Parts 3A and 3B are expected in the first quarter of 2027, and a Phase 2 study in MetALD and ALD is planned for the second half of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001104659-26-128856.

Written from the filing by Shamburg Markets. Figures are as reported by the company.